A randomized study of ceftriaxone for the prevention of infections in hospitalized patients with advanced cirrhosis.

"CONFLICTS OF INTEREST Zachary Fricker has received research support from the AASLD Foundation; Mallinckrodt Pharmaceuticals; Lipocine, Inc.; and consulting fees from Back Bay Life Sciences and Pick Research. Gordon Jiang consults for Olix and received grants from Pfizer and Gilead. Michael Curry has received research support from Sonic Incytes and has received consulting fees from Mallinckrodt, Albireo, Alexion, and Sonic Incytes. The remaining authors (Het Patel, Annabel McLaughlin, Sofia Izunza Barba, and Sebastian Niezen) have no conflicts to report."

"FUNDING INFORMATION Financial support for this study was provided by the AASLD Foundation Advanced/Transplant Hepatology Award. This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR002541 and financial contributions from Harvard University and its affiliated academic health care centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the National Institutes of Health."

"This study was approved by the Beth Israel Deaconess Medical Center Institutional Review Board and registered through ClinicalTrials.gov (NCT04218695). All research was conducted in accordance with both the Declarations of Helsinki and Istanbul, and all subjects or a legally authorized representative provided written informed consent before participation. Funding for the study was from the AASLD Foundation."